Rezolute Inc (RZLT):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Rezolute Inc (RZLT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C12385
◆発行会社(調査会社):GlobalData
◆発行日:2018年12月
◆ページ数:54
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Rezolute Inc (Rezolute) formerly known as AntriaBio Inc, is a clinical stage biopharmaceutical company specializing in the development of innovative drug therapies for the treatment of metabolic and orphan diseases. Its pipeline product portfolio includes AB101, a microsphere formulation of PEGylated human recombinant insulin for use in type 1 and type 2 diabetes for the control of hyperglycemia; RZ358, an intravenous monoclonal antibody for congenital hyperinsulinism; RZ402, an oral plasma kallikrein inhibitor for diabetic macular edema; and RZ602, for the treatment of hereditary angioedema. The company develops new product candidates by proprietary formulation and manufacturing capabilities. Rezolute is headquartered in Louisville, Colorado, the US.

Rezolute Inc (RZLT) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Rezolute Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Rezolute Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Rezolute Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Rezolute Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Rezolute Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Rezolute Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
AntriaBio Raises USD6.7 Million in Venture Financing 12
AntriaBio Raises USD3.4 Million in Venture Financing 13
AntriaBio Raises US$7.3 Million In Venture Financing 14
Rezolute Raises Funds Through Venture Financing 15
Private Equity 16
Rezolute Raises USD4 Million in Second Tranche of Private Placement of 12% Notes Due 2019 16
Rezolute Raises USD0.7 Million in First Tranche of Private Placement of 12% Notes Due 2019 17
Lincoln Park Capital Fund to Invest up to USD10 Million in Rezolute 18
Merger 19
AntriaBio And Fits My Style Complete Merger 19
Licensing Agreements 20
Rezolute Enters into Licensing Agreement with XOMA 20
AntriaBio Enters into Licensing Agreement with ActiveSite Pharma 21
AntriaBio Enters Into Licensing Agreement With pH Pharma 22
Equity Offering 23
Rezolute Plans to Raise up to USD11.7 Million in Public Offering of Shares 23
AntriaBio Plans to Raise up to USD13.7 Million in Public Offering of Shares 24
AntriaBio Raises USD12.8 Million in Private Placement of Shares 25
AntriaBio Raises USD4.5 Million in Private Placement of Shares 26
AntriaBio Raises USD1.55 Million in Private Placement of Shares 27
AntriaBio Raises USD2.22 Million in Private Placement of Shares 28
AntriaBio Plans to Raise Funds through Public Offering of Shares 29
AntriaBio Raises USD0.1 Million in Private Placement of Shares 30
AntriaBio Raises USD2.23 Million in Private Placement of Shares 31
AntriaBio Raises USD0.46 Million in Private Placement of Shares 32
AntriaBio Raises USD12 Million in Private Placement of Shares and Warrants 33
AntriaBio Raises USD0.8 Million in Private Placement of Shares 34
AntriaBio Raises USD3.3 Million in Private Placement of Shares 35
AntriaBio Raises USD0.1 Million in Private Placement of Shares 36
AntriaBio Raises USD1 Million in Private Placement of Series A Preferred Stock 37
AntriaBio Raises USD6.4 Million in Private Placement of Shares 38
AntriaBio Raises USD3.34 Million in Private Placement of Shares 39
Rezolute Inc – Key Competitors 40
Rezolute Inc – Key Employees 41
Rezolute Inc – Locations And Subsidiaries 42
Head Office 42
Other Locations & Subsidiaries 42
Recent Developments 43
Corporate Communications 43
May 16, 2018: Rezolute Announces Appointment of Keith Vendola as Chief Financial Officer 43
Apr 04, 2018: Rezolute Announces Appointment of Hoyoung as Vice Chairman of its Board of Directors 44
Oct 09, 2017: AntriaBio Appoints Nektar Therapeutics CFO to its Board of Directors 45
Oct 04, 2017: AntriaBio Appoints Dr. Robert Bhisitkul to its Scientific Advisory Board 46
Product News 47
03/23/2017: XOMA provides update on pipeline program XOMA 358 at the 2017 ENDO Meeting 47
03/22/2017: Antriabio Appoints Two Pharmaceutical Executives To Its Board Of Directors 48
01/31/2017: XOMA Establishes Proof-of-Concept for 358 in Congenital Hyperinsulinism and Hypoglycemia Post-Bariatric Surgery 49
Product Approvals 50
Jun 05, 2017: AntriaBio Files Investigational New Drug Application for Once-Weekly Basal Insulin AB101 50
Clinical Trials 51
Oct 17, 2017: AntriaBio Announces Selection of Lead Oral Plasma Kallikrein Inhibitor AB-402 Candidate for Treatment of DR and DME 51
Oct 17, 2017: AntriaBio Announces Selection of Lead Oral Plasma Kallikrein Inhibitor AB-602 Candidate for Treatment of HAE 52
May 01, 2017: AntriaBio Formally Engages CRO for the Conduct of its Phase I First-in-Human Clinical Trial of AB101 53
Appendix 54
Methodology 54
About GlobalData 54
Contact Us 54
Disclaimer 54

List of Tables
Rezolute Inc, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Rezolute Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Rezolute Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Rezolute Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Rezolute Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Rezolute Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
AntriaBio Raises USD6.7 Million in Venture Financing 12
AntriaBio Raises USD3.4 Million in Venture Financing 13
AntriaBio Raises US$7.3 Million In Venture Financing 14
Rezolute Raises Funds Through Venture Financing 15
Rezolute Raises USD4 Million in Second Tranche of Private Placement of 12% Notes Due 2019 16
Rezolute Raises USD0.7 Million in First Tranche of Private Placement of 12% Notes Due 2019 17
Lincoln Park Capital Fund to Invest up to USD10 Million in Rezolute 18
AntriaBio And Fits My Style Complete Merger 19
Rezolute Enters into Licensing Agreement with XOMA 20
AntriaBio Enters into Licensing Agreement with ActiveSite Pharma 21
AntriaBio Enters Into Licensing Agreement With pH Pharma 22
Rezolute Plans to Raise up to USD11.7 Million in Public Offering of Shares 23
AntriaBio Plans to Raise up to USD13.7 Million in Public Offering of Shares 24
AntriaBio Raises USD12.8 Million in Private Placement of Shares 25
AntriaBio Raises USD4.5 Million in Private Placement of Shares 26
AntriaBio Raises USD1.55 Million in Private Placement of Shares 27
AntriaBio Raises USD2.22 Million in Private Placement of Shares 28
AntriaBio Plans to Raise Funds through Public Offering of Shares 29
AntriaBio Raises USD0.1 Million in Private Placement of Shares 30
AntriaBio Raises USD2.23 Million in Private Placement of Shares 31
AntriaBio Raises USD0.46 Million in Private Placement of Shares 32
AntriaBio Raises USD12 Million in Private Placement of Shares and Warrants 33
AntriaBio Raises USD0.8 Million in Private Placement of Shares 34
AntriaBio Raises USD3.3 Million in Private Placement of Shares 35
AntriaBio Raises USD0.1 Million in Private Placement of Shares 36
AntriaBio Raises USD1 Million in Private Placement of Series A Preferred Stock 37
AntriaBio Raises USD6.4 Million in Private Placement of Shares 38
AntriaBio Raises USD3.34 Million in Private Placement of Shares 39
Rezolute Inc, Key Competitors 40
Rezolute Inc, Key Employees 41
Rezolute Inc, Subsidiaries 42

List of Figures
Rezolute Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Rezolute Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Rezolute Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Rezolute Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Rezolute Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Rezolute Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Rezolute Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Rezolute Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Rezolute Inc (RZLT):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Lipocine Inc (LPCN):製薬・医療:M&Aディール及び事業提携情報
    Summary Lipocine Inc (Lipocine) is a pharmaceutical company that develops and commercializes treatment for men's and women's health. The company’s pipeline products for men’s health include LPCN 1111 and LPCN 1021; and for women’s health include LPCN 1107. Its LPCN 1111 is an oral testosterone produ …
  • Mytrus Inc-製薬・医療分野:企業M&A・提携分析
    Summary Mytrus Inc (Mytrus) is an e-clinical technology company that specializes in patient-centered electronic informed consent and data collection tools. The company’s technology includes Enroll, an electronic informed consent and patient enrollment system for clinical trials. Mytrus develops new …
  • MS&AD Insurance Group Holdings, Inc.:企業のM&A・事業提携・投資動向
    MS&AD Insurance Group Holdings, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's MS&AD Insurance Group Holdings, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports …
  • Ultra Electronics 3Phoenix, Inc.:企業の戦略・SWOT・財務情報
    Ultra Electronics 3Phoenix, Inc. - Strategy, SWOT and Corporate Finance Report Summary Ultra Electronics 3Phoenix, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Doosan Corporation:企業の戦略・SWOT・財務情報
    Doosan Corporation - Strategy, SWOT and Corporate Finance Report Summary Doosan Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Theranostics Health Inc:医療機器:M&Aディール及び事業提携情報
    Summary Theranostics Health Inc (Theranostics), a subsidiary of Avant Diagnostics Inc is a healthcare service provider that offers protein based solutions. The company provides protein based discovery and translational research services. Its products include molecular navigation of targeted therapie …
  • Inter Parfums Inc (IPAR):企業の財務・戦略的SWOT分析
    Summary Inter Parfums Inc (Inter Parfums) is a consumer goods company that manufactures, develops, and markets fragrance and beauty care products. The company’s products include cosmetics, fragrances, personal care products, and fragrance related products. Its personal care products comprise cosmeti …
  • Bakkavor Group Limited:企業の戦略・SWOT・財務情報
    Bakkavor Group Limited - Strategy, SWOT and Corporate Finance Report Summary Bakkavor Group Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Westminster Group plc:企業の戦略・SWOT・財務分析
    Westminster Group plc - Strategy, SWOT and Corporate Finance Report Summary Westminster Group plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Concordia International Corp (CXR)-製薬・医療分野:企業M&A・提携分析
    Summary Concordia International Corp (Concordia), formerly Concordia Healthcare Corp is a healthcare products provider that offers orphan drugs. The company undertakes the management and acquisition of legacy pharmaceutical products, orphan drugs and medical devices for diabetics. Its products compr …
  • AltaGas Ltd (ALA):石油・ガス:M&Aディール及び事業提携情報
    Summary AltaGas Ltd (AltaGas) is an energy utility. The company undertakes activities related to extraction, transmission, distribution and storage of natural gas. AltaGas generates electricity utilizing diverse fuel sources, including wind, run-of-river hydro, geothermal and gas-fired generation pl …
  • New Zealand Post Limited:企業の戦略的SWOT分析
    New Zealand Post Limited - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Teradyne Inc (TER):企業の財務・戦略的SWOT分析
    Teradyne Inc (TER) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Aegean Airlines S.A.:企業の戦略・SWOT・財務情報
    Aegean Airlines S.A. - Strategy, SWOT and Corporate Finance Report Summary Aegean Airlines S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Cebu Air Inc:戦略・SWOT・企業財務分析
    Cebu Air Inc - Strategy, SWOT and Corporate Finance Report Summary Cebu Air Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Seres Therapeutics Inc (MCRB):企業の財務・戦略的SWOT分析
    Summary Seres Therapeutics Inc (Seres), is a microbiome therapeutics platform company that develops a novel class of biological drugs. The company creates a new class of medicines to treat diseases resulting from functional deficiencies in the microbiome, a condition known as dysbiosis. The company’ …
  • Catalyst Biosciences Inc (CBIO):企業の財務・戦略的SWOT分析
    Summary Catalyst Biosciences Inc (Catalyst Biosciences) is a clinical-stage biopharmaceutical company that develops protease-based advanced medicines to treat hematological indications. The company specializes in hemostasis, with focus on subcutaneous prophylaxis of hemophilia and surgery, and anti- …
  • Altri SGPS SA (ALTR):企業の財務・戦略的SWOT分析
    Altri SGPS SA (ALTR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Harvard Stem Cell Institute:製薬・医療:M&Aディール及び事業提携情報
    Summary Harvard Stem Cell Institute (HSCI) a subsidiary of Harvard University is a healthcare institute that conducts research on advance stem cell science using stem cell biology to develop new treatments and cures for disease. The institute provides research programs such as disease programs, core …
  • Ion Beam Applications SA (IBAB):企業の財務・戦略的SWOT分析
    Ion Beam Applications SA (IBAB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆